PE-22-28 is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
Antagonizes TREK-1 (TWIK-related potassium channel), blocking potassium conductance to depolarize neurons and increase membrane excitability. Enhances serotonergic neuron firing and elevates monoamine neurotransmission, producing rapid antidepressant effects within 4 days by stimulating hippocampal neurogenesis.
How Does PE-22-28 Work in the Body?
PE-22-28 (PE-22-28 (spadin analog, TREK-1 inhibitor)) is a Ion channel inhibitor peptide. Synthetic shortened analog of spadin with enhanced TREK-1 potassium channel specificity and brain stability.
Understanding its mechanism of action helps researchers design protocols and predict outcomes.
What Is the Primary Mechanism of PE-22-28?
Antagonizes TREK-1 (TWIK-related potassium channel), blocking potassium conductance to depolarize neurons and increase membrane excitability. Enhances serotonergic neuron firing and elevates monoamine neurotransmission, producing rapid antidepressant effects within 4 days by stimulating hippocampal neurogenesis.
This mechanism operates at the cellular level and influences downstream pathways that produce the observable effects researchers study.
What Biological Pathways Does PE-22-28 Affect?
As a Ion channel inhibitor peptide, PE-22-28 interacts with specific receptors and signaling cascades. These pathways are responsible for the compound's effects on rapid antidepressant effects (4 days vs 4-6 weeks for SSRIs), hippocampal neurogenesis, enhanced synaptogenesis.
The multi-pathway activity is what gives PE-22-28 its broad potential application range — each pathway contributes to different aspects of the overall effect profile.
How Quickly Does PE-22-28's Mechanism Take Effect?
With a half-life of 14-23 hours in rodents, PE-22-28 begins interacting with its target receptors within minutes of administration. However, the downstream biological effects take longer to manifest — typically days to weeks depending on the application.
Standard cycles run 4-8 weeks because that's the timeframe needed for the mechanism to produce measurable, cumulative results.
What Does the Research Say?
Superior TREK-1 inhibition (IC50: 0.12 nM vs 40-60 nM for native spadin) with rapid antidepressant effects in rodent stress models. 4-day onset compared to weeks for conventional antidepressants. No human clinical trials.
Demonstrates antidepressant onset in 4 days versus 4-6 weeks for conventional medications — if human efficacy confirms, this would be the fastest-acting peptide antidepressant.
Bottom Line on PE-22-28's Mechanism
PE-22-28 works through ion channel inhibitor peptide activity to influence rapid antidepressant effects (4 days vs 4-6 weeks for SSRIs), hippocampal neurogenesis, enhanced synaptogenesis. Its mechanism involves multiple pathways, which is why it shows potential across several research applications.
See our PE-22-28 benefits guide for how this mechanism translates to practical outcomes.
Complete Guide
PE-22-28 : Benefits, Dosage, Side Effects & Research
Related Reading
- PE-22-28 Dosage Guide
- PE-22-28 Benefits
- PE-22-28 Side Effects
- PE-22-28 Stacking Guide
- PE-22-28 Cycle Guide
- PE-22-28 Research
Calculate Your PE-22-28 Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for PE-22-28.
Open Calculator →Research-Grade Sourcing
If you're going to research PE-22-28, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is PE-22-28?
PE-22-28 (PE-22-28 (spadin analog, TREK-1 inhibitor)) is a Ion channel inhibitor peptide. Synthetic shortened analog of spadin with enhanced TREK-1 potassium channel specificity and brain stability. It is researched for rapid antidepressant effects (4 days vs 4-6 weeks for SSRIs), hippocampal neurogenesis, enhanced synaptogenesis.
What is the recommended PE-22-28 dosage?
Common dosages: 100-500 mcg daily administered once daily via subcutaneous injection (proposed). Cycle length: 4-8 weeks. Half-life: 14-23 hours in rodents. Use our peptide calculator for exact reconstitution math.
What are the side effects of PE-22-28?
Minimal toxicity in animal models. Potential hypertension from enhanced monoamine activity. Human safety unknown. GABAergic disruption possible.
Is PE-22-28 safe?
PE-22-28 has shown a preliminary safety profile in research. Not FDA-approved. Investigational research peptide only. All research should follow appropriate safety protocols.